Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a
Se aplică pentru toate denumirile comerciale şi formele farmaceutice corespunzătoare concentraţiei de 20 mg
Yüklə 4,39 Mb.
|
Se aplică pentru toate denumirile comerciale şi formele farmaceutice corespunzătoare concentraţiei de 20 mg. A02BC02 PANTOPRAZOLUM COMPR. FILM. GASTROREZ. 40 mg CONTROLOC 40 mg 40 mg ALTANA PHARMA AG Prescriere limitată: Boala de reflux gastro-esofagian. Prescriere limitată: Sindromul Zollinger-Ellison Prescriere limitată: Tratamentul ulcerului gastric şi duodenal.
CONTROLOC 40 mg LIOFILIZAT 40 mg ALTANA PHARMA AG PENTRU SOLUŢIE INJECTABILĂ ________________________________________________________________________________ ______________________________________________________________________________ | 158 |A02BC05| ESOMEPRAZOLUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A02BC05 ESOMEPRAZOLUM COMPR. FILM. GASTROREZ. 40 mg NEXIUM 40 mg 40 mg ASTRAZENECA AB
Prescriere limitată: Sindromul Zollinger-Ellison. Se aplică pentru toate denumirile comerciale şi formele farmaceutice corespunzătoare concentraţiei de 40 mg. A02BC05 ESOMEPRAZOLUM LIOF. PT. SOL. INJ./ 40 mg PERF.
NEXIUM(R) 40 mg ASTRAZENECA AB A02BC05 ESOMEPRAZOLUM COMPR. FILM. GASTROREZ. 20 mg NEXIUM 20 mg 20 mg ASTRAZENECA AB Prescriere limitată: Tratamentul ulcerului gastric şi duodenal. Prescriere limitată: Menţinerea rezultatelor terapiei refluxului gastro-esofagian. Prescriere limitată: Profilaxia ulcerului gastro-duodenal asociat tratamentului cu antiinflamatoare nesteroidiene pe termen lung la pacienţii cu factori de risc gastrointestinali.
| 159 |A02BX02| SUCRALFATUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A02BX02 SUCRALFATUM COMPR. 1 g GASTROFAIT 1 g E.I.P.I.CO. MED S.R.L. SUCRALAN(R) 1 g LANNACHER HEILMITTEL GMBH VENTER 1 g KRKA D.D. ________________________________________________________________________________ ______________________________________________________________________________ | 160 |A02BX05| BISMUTHI SUBCITRAS | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A02BX05 BISMUTHI SUBCITRAS COMPR. FILM. 120 mg DE-NOL 120 mg ASTELLAS PHARMA EUROPE B.V.
________________________________________________________________________________ ______________________________________________________________________________ | 161 |A03AB06| OTILONIUM BROMIDUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A03AB06 OTILONIUM BROMIDUM COMPR. FILM. 40 mg SPASMOMEN(R) 40 mg A. MENARINI IND. FARM. RIUNITE SRL ________________________________________________________________________________
| 162 |A06AD15| MACROGOLUM* (2) | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A06AD15 MACROGOLUM PULB. PT. SOL. ORALĂ FORTRANS(R) BEAUFOUR IPSEN INT. ________________________________________________________________________________ ______________________________________________________________________________ | 163 |A07AA11| RIFAXIMINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A07AA11 RIFAXIMINUM COMPR. FILM. 200 mg NORMIX 200 mg 200 mg ALFA WASSERMANN SPA ________________________________________________________________________________ ______________________________________________________________________________ | 164 |A07EA06| BUDESONIDUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________
BUDENOFALK 3 mg DR. FALK PHARMA GMBH ________________________________________________________________________________
| 165 |A07XA04| RACECADOTRILUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A07XA04 RACECADOTRILUM CAPS. 100 mg HIDRASEC 100 mg 100 mg LAB. FOURNIER SA
HIDRASEC 10 mg 10 mg LAB. FOURNIER SA A07XA04 RACECADOTRILUM PULB. PT. SOL. ORALĂ 30 mg HIDRASEC 30 mg 30 mg LAB. FOURNIER SA ________________________________________________________________________________
| 166 |A08AA10| SIBUTRAMINUM**** | Protocol: A003E | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A08AA10 SIBUTRAMINUM CAPS. 10 mg LINDAXA 10 10 mg ZENTIVA A.S. REDUCTIL 10 mg 10 mg ABBOTT GMBH & CO.KG A08AA10 SIBUTRAMINUM CAPS. 15 mg LINDAXA 15 15 mg ZENTIVA A.S. REDUCTIL 15 mg 15 mg ABBOTT GMBH & CO.KG ________________________________________________________________________________ ______________________________________________________________________________ | 167 |A08AB01| ORLISTATUM**** | Protocol: A001E | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A08AB01 ORLISTATUM CAPS. 120 mg XENICAL 120 mg 120 mg ROCHE REGISTRATION LTD. ________________________________________________________________________________ ______________________________________________________________________________ | 168 |A08AX01| RIMONABANTUM**** | Protocol: A031E | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A08AX01 RIMONABANTUM COMPR. FILM. 20 mg ACOMPLIA 20 mg 20 mg SANOFI AVENTIS ________________________________________________________________________________ ______________________________________________________________________________ | 169 |A11CC03| ALFACALCIDOLUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A11CC03 ALFACALCIDOLUM CAPS. MOI 0.25 µg ALPHA D3 0,25 µg 0.25 µg TEVA PHARMACEUTICALS SRL
ALPHA D3 0.50 µg 0.50 µg TEVA PHARMACEUTICALS S.R.L. ________________________________________________________________________________ ______________________________________________________________________________ | 170 |A16AX01| ACIDUM TIOCTICUM (ALFA-LIPOICUM)**# | Protocol: A021E | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A16AX01 ACIDUM TIOCTICUM SOL. PERF. 12 mg/ml (ALFA-LIPOICUM) THIOGAMMA(R) TURBO-SE 12 mg/ml WORWAG PHARMA GMBH & CO.KG THIOGAMMA(R) TURBO-SET 12 mg/ml WORWAG PHARMA GMBH & CO.KG
(ALFA-LIPOICUM) THIOGAMMA(R) 600 INJEKT 30 mg/ml WORWAG PHARMA GMBH & CO.KG
(ALFA-LIPOICUM) THIOGAMMA(R) 600 oral 600 mg WORWAG PHARMA GMBH & CO.KG ________________________________________________________________________________ ______________________________________________________________________________ | 171 |B01AB04| DALTEPARINUM**# | Protocol: B008D | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AB04 DALTEPARINUM SOL. INJ. 10000 ui/ml FRAGMIN 10000 UI/ml 10000 ui/ml PFIZER EUROPE MA EEIG
FRAGMIN 15000 UI/0,6 ml 15000 ui/0.6 ml PFIZER EUROPE MA EEIG B01AB04 DALTEPARINUM SOL. INJ. 2500 ui/0.2 ml FRAGMIN 2500 UI/0,2 ml 2500 ui/0.2 ml PFIZER EUROPE MA EEIG B01AB04 DALTEPARINUM SOL. INJ. 5000 ui/0.2 ml FRAGMIN 5000 UI/0,2 ml 5000 ui/0.2 ml PFIZER EUROPE MA EEIG B01AB04 DALTEPARINUM SOL. INJ. 7500 ui/0.3 ml FRAGMIN 7500 UI/0,3 ml 7500 ui/0.3 ml PFIZER EUROPE MA EEIG ________________________________________________________________________________
| 172 |B01AB05| ENOXAPARINUM**# | Protocol: B008D | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui anti-Xa/0.2 ml CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS anti-Xa/0.2 ml
anti-Xa/0,4 ml CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS anti-Xa/0.4 ml B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui anti-Xa/0.6 ml CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS anti-Xa/0.6 ml B01AB05 ENOXAPARINUM SOL. INJ. 8000 ui anti-Xa/0.8 ml CLEXANE 8000 ui 8000 ui anti-Xa/0.8 ml LAB. AVENTIS anti-Xa/0.8 ml B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui anti-Xa/0.2 ml CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS anti-Xa/0.2 ml B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui anti-Xa/0,4 ml CLEXANE 4000 ui 4000 ui LAB. AVENTIS anti-Xa/0.4 ml anti-Xa/0,4 ml B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui anti-Xa/0.6 ml CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS anti-Xa/0.6 ml ________________________________________________________________________________
| 173 |B01AB06| NADROPARINUM**# | Protocol: B008D | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AB06 NADROPARINUM SOL. INJ. 11400 ui AXa/0.6 ml FRAXODI 11400 UI 11400 ui AXa/0.6 ml GLAXO GROUP LTD. anti-factor Xa/0,6 ml
AXa/0.8 ml FRAXODI 15200 UI 15200 ui AXa/0.8 ml GLAXO GROUP LTD. anti-factor Xa/0.8 ml B01AB06 NADROPARINUM SOL. INJ. 2850 ui AFXa/0.3 ml FRAXIPARINE(R) 2850 UI 2850 ui AFXa/0.3 ml GLAXO GROUP LTD. anti-factor Xa/0,3 ml B01AB06 NADROPARINUM SOL. INJ. 3800 ui AFXa/0.4 ml FRAXIPARINE(R) 3800 UI 3800 ui AFXa/0.4 ml GLAXO GROUP LTD. anti-factor Xa/0,4 ml B01AB06 NADROPARINUM SOL. INJ. 5700 ui AFXa/0.6 ml FRAXIPARINE(R) 5700 UI 5700 ui AFXa/0.6 ml GLAXO GROUP LTD. anti-factor Xa/0.6 ml B01AB06 NADROPARINUM SOL. INJ. 7600 ui AXa/0.8 ml FRAXIPARINE(R) 7600 UI 7600 ui AXa/0.8 ml GLAXO GROUP LTD. anti-factor Xa/0,8 ml ________________________________________________________________________________
| 174 |B01AB08| REVIPARINUM**# | Protocol: B008D | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AB08 REVIPARINUM SOL. INJ. 1432 ui/0.25 ml CLIVARIN(R) 1432 UI/0.25 ml 1432 ui/0.25 ml ABBOTT GMBH & CO.KG
CLIVARIN(R) 3436 UI/0,6 ml 3436 ui/0.6 ml ABBOTT GMBH & CO.KG ________________________________________________________________________________
| 175 |B01AB10| TINZAPARINUM**# | Protocol: B008D | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AB10 TINZAPARINUM SOL. INJ. 10000 u ANTIF. Xa/ml INNOHEP 10000 U ANTIF. Xa/ml LEO PHARMACEUTICAL PRODUCTS
INNOHEP 20000 U ANTIF. Xa/ml LEO PHARMACEUTICAL PRODUCTS
________________________________________________________________________________ ______________________________________________________________________________ | 176 |B01AB11| SULODEXIDUM** | Protocol: B014I | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AB11 SULODEXIDUM CAPS. MOI 250 ULS VESSEL DUE F 250 ULS ALFA WASSERMANN SPA
VESSEL DUE F 600 ULS/2 ml ALFA WASSERMANN SPA ________________________________________________________________________________
| 177 |B01AC04| CLOPIDOGRELUM** | Protocol: B009I;| | | | | B010I | |_______|_______|____________________________________________|_________________| ________________________________________________________________________________ DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AC04 CLOPIDOGRELUM COMPR. FILM. 75 mg PLAVIX 75 mg 75 mg SANOFI PHARMA - BRISTOL MYERS SQUIBB Cod restricţie 1719: Prevenţia recurenţei accidentului vascular ischemic sau a accidentului ischemic tranzitor la pacienţii cu istoric de episoade ischemice cerebrovasculare conform protocolului de prescriere. Cod restricţie 1722: Prevenţia recurenţei infarctului de miocard sau a anginei instabile la pacienţii cu istoric de evenimente ischemice cardiace simptomatice conform protocolului de prescriere. Cod restricţie 3008: Tratamentul antiagregant al ateromatozei extensive (carotidiene, coronariene şi periferice).
| 178 |B01AC30| COMBINATII (DIPYRIDAMOLUM + ACIDUM | Protocol: B010I | | | | ACETYLSALICYLICUM)** | | |_______|_______|____________________________________________|_________________| ________________________________________________________________________________ DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AC30 COMBINATII CAPS. ELIB. MODIF. (DIPYRIDAMOLUM + ACIDUM
ACETYLSALICYLICUM) AGGRENOX BOEHRINGER INGELHEIM INTERNATIONAL GMBH ________________________________________________________________________________ ______________________________________________________________________________ | 179 |B01AX05| FONDAPARINUX SODIUM**# | Protocol: B008D | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AX05 FONDAPARINUX SODIUM SOL. INJ. ÎN SERINGĂ 10 mg/0.8 ml PREUMPLUTĂ ARIXTRA 10 mg/0.8 ml 10 mg/0.8 ml GLAXO GROUP LTD. B01AX05 FONDAPARINUX SODIUM SOL. INJ. ÎN SERINGĂ 2.5 mg/0.5 ml PREUMPLUTĂ ARIXTRA 2.5 mg/0.5 ml 2.5 mg/0.5 ml GLAXO GROUP LTD.
PREUMPLUTĂ ARIXTRA 5 mg/0.4 ml 5 mg/0.4 ml GLAXO GROUP LTD.
PREUMPLUTĂ ARIXTRA 7.5 mg/0.6 ml 7.5 mg/0.6 ml GLAXO GROUP LTD. ________________________________________________________________________________ ______________________________________________________________________________ | 180 |B03AC02| COMPLEX DE HIDROXID DE FER (III) SUCROZA | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B03AC02 COMPLEX DE HIDROXID SOL. INJ./PERF. 20 mg/ml DE FER (III) SUCROZA VENOFER(R) 20 mg/ml VIFOR FRANCE S.A. Cod restricţie 2070: Anemie feriprivă, la pacienţii care au prezentat o reacţie de hipersensibilitate documentată la fier polimaltozat şi la care este indicată administrarea continuă intravenoasă. ________________________________________________________________________________ ______________________________________________________________________________ | 181 |B01AC18| TRIFLUSALUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AC18 TRIFLUSALUM CAPS. 300 mg AFLEN(R) 300 mg ZENTIVA S.A. ________________________________________________________________________________ ______________________________________________________________________________ | 182 |C01BB02| MEXILETINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ C01BB02 MEXILETINUM CAPS. 200 mg MEXITIL(R) 200 mg 200 mg BOEHRINGER INGELHEIM INT. GMBH
________________________________________________________________________________ ______________________________________________________________________________ | 183 |C01EB17| IVABRADINUM** | Protocol: C003I | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ C01EB17 IVABRADINUM COMPR. FILM. 5 mg CORLENTOR 5 mg 5 mg LES LAB. SERVIER
CORLENTOR 7,5 mg 7.5 mg LES LAB. SERVIER ________________________________________________________________________________
| 184 |C02AC05| MOXONIDINUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________
Yüklə 4,39 Mb. Dostları ilə paylaş:
|